open access

Vol 15, No 1 (2019)
Other materials agreed with the Editors
Published online: 2019-04-16
Get Citation

Current literature review

Maciej Kawecki
DOI: 10.5603/OCP.2019.0009
·
Oncol Clin Pract 2019;15(1).

open access

Vol 15, No 1 (2019)
CURRENT LITERATURE REVIEW
Published online: 2019-04-16

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Current literature review

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 1 (2019)

Article type

Other materials agreed with the Editors

Published online

2019-04-16

DOI

10.5603/OCP.2019.0009

Bibliographic record

Oncol Clin Pract 2019;15(1).

Authors

Maciej Kawecki

References (6)
  1. Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018; 4(5): e180013.
  2. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10111): 2461–2471.
  3. Shitara K, Özgüroğlu M, Bang YJ, et al. KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392(10142): 123–133.
  4. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018; 29(10): 2052–2060.
  5. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019 [Epub ahead of print]: JCO1800050.
  6. Primrose J, Fox R, Palmer D, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. Journal of Clinical Oncology. 2017; 35(15_suppl): 4006–4006.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl